Evidence map›Paper›PMID 39443144›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

The Influence of the Estrous Cycle on Neuropeptide S Receptor-Mediated Behaviors.

Paula Carvalho Costa, Brisa Salinas, Alaina Wojciechowski, Susan K Wood, Scott Runyon, Stewart D Clark

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paula Carvalho CostaDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.).
Brisa SalinasDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.).
Alaina WojciechowskiDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.).
Susan K WoodDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.).
Scott RunyonDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.).
Stewart D ClarkDepartment of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York (P.C.C., B.S., A.W., S.D.C.); Department of Pharmacology Physiology and Neuroscience, University of South Carolina School of Medicine (S.K.W.) and Dorn VA Medical Center (S.K.W.), Columbia, South Carolina; and Research Triangle Institute, Center for Drug Discovery, Research Triangle Park, North Carolina (S.R.) stewartc@buffalo.edu.

Funding

Discovering Small Molecule Biased Agonists for the Neuropeptide S ReceptorR01MH122196 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI CLARK, STEWART DONALDSON, RUNYON, SCOTT P · 2020 to 2022
$2.3M
NIMH NIH HHS R01 MH122196
6 · The paper itself

Abstract

The neuropeptide S receptor (NPSR) has been identified as a potential therapeutic target for anxiety and post-traumatic stress disorder. Central administration of neuropeptide S (NPS) in male mice produces anxiolytic-like effects, hyperlocomotion, and memory enhancement. Currently, the literature is limited in the number of studies investigating the effects of NPS in female test subjects despite females facing a higher prevalence of anxiety-related pathology, as well as greater risk for adverse effects while taking psychoactive drugs. Moreover, no previous studies have considered the influence of estrous cycle on the effects of NPS. The present study investigates whether NPS-mediated behavioral phenotypes seen in males translate to females, and whether they are affected by estrous cycle stage. Female C57BL/6NCr mice were intracerebroventricularly cannulated and underwent behavioral paradigms to test locomotion, anxiety, and memory. Estrous cycle stage was determined through examination of vaginal cytology. Our results provide evidence that NPS-mediated behaviors are influenced by the estrous cycle. Administration of NPS decreased anxiety-like behaviors more robustly when the female mice were in high estrogen stages of the estrous cycle. Therefore, the desired anxiolytic-like effects of targeting the NPSR are intact in female mice. However, these effects may to be influenced by the stage of the estrous cycle. The NPSR remains a strong potential drug target for new anxiolytic compounds and based on our initial observations further studies exploring the interaction of estrous cycle and the NPS system are warranted. SIGNIFICANCE STATEMENT: The neuropeptide S (NPS) receptor has been identified as a potential target for treating anxiety, a condition that is most prevalent in females. Therefore, the potential interaction of estrous cycle with the NPS system described in the present study is an important first step in understanding the function of the NPS system in females.

Indexed as

AnxietyBehavior, AnimalEstrous CycleMice, Inbred C57BLReceptors, NeuropeptideAnimalsFemaleLocomotionMaleMemoryMiceNeuropeptidesNeuropeptidesneuropeptide S, mouseneuropeptide S receptor, mouseReceptors, Neuropeptide

Identifiers

PMID39443144
PMCPMC11585311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.